TRCT
GANX icon

Tower Research Capital (TRC)’s Gain Therapeutics GANX Stock Holding History

Tower Research Capital (TRC)’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7K Sell
5,506
-1,353
-20% -$2.94K ﹤0.01% 3877
2025
Q4 		$22.1K Buy
6,859
+4,795
+232% +$12.8K ﹤0.01% 3021
2025
Q3 		$3.65K Buy
2,064
+1,119
+118% +$1.89K ﹤0.01% 4469
2025
Q2 		$1.7K Sell
945
-1,487
-61% -$2.75K ﹤0.01% 4760
2025
Q1 		$4.64K Buy
+2,432
New +$5.39K ﹤0.01% 4222
2024
Q4 		– Sell
-4,842
Closed -$8.62K – 5792
2024
Q3 		$8.62K Buy
4,842
+3,113
+180% +$3.91K ﹤0.01% 3948
2024
Q2 		$2.21K Sell
1,729
-2,903
-63% -$7.54K ﹤0.01% 5040
2024
Q1 		$17.5K Sell
4,632
-260
-5% -$1.08K ﹤0.01% 3122
2023
Q4 		$16K Buy
4,892
+2,022
+70% +$5.62K ﹤0.01% 3798
2023
Q3 		$9.41K Sell
2,870
-1,477
-34% -$5.6K ﹤0.01% 4221
2023
Q2 		$19.5K Sell
4,347
-2,497
-36% -$12.2K ﹤0.01% 3405
2023
Q1 		$33K Sell
6,844
-308
-4% -$1.26K ﹤0.01% 2893
2022
Q4 		$23K Buy
7,152
+1,891
+36% +$5.91K ﹤0.01% 2992
2022
Q3 		$17K Buy
5,261
+4,545
+635% +$17.1K ﹤0.01% 4064
2022
Q2 		$3K Buy
716
+123
+21% +$424 ﹤0.01% 5374
2022
Q1 		$2K Sell
593
-577
-49% -$2.41K ﹤0.01% 5548
2021
Q4 		$7K Buy
1,170
+615
+111% +$4.24K ﹤0.01% 4909
2021
Q3 		$4K Buy
555
+483
+671% +$4.04K ﹤0.01% 4970
2021
Q2 		$0 Buy
+72
New +$812 ﹤0.01% 5595

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Tower Research Capital (TRC)'s GANX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Gain Therapeutics (GANX) stake by 20% in Q1 2026, selling an estimated $2.94K and leaving 5,506 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3877.

Tower Research Capital (TRC) first reported a position in GANX in Q2 2021 and has held it in 19 quarters since. The position peaked at $33K in Q1 2023. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Tower Research Capital (TRC) held 5,506 shares of Gain Therapeutics worth $10.7K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,353 Gain Therapeutics shares in Q1 2026, an estimated $2.94K.
  • Gain Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3877 holding.
  • Tower Research Capital (TRC) first reported a position in Gain Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Gain Therapeutics position peaked at $33K in Q1 2023.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.